Kenox Pharmaceuticals Inc. and Lactiga US, Inc. are pleased to announce a strategic collaboration to advance the development of novel, groundbreaking, mucosal-targeted Secretory IgA (sIgA) therapies for immunodeficient patients. This partnership is supported by a significant multi-million-dollar STTR grant awarded to Lactiga by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
This collaboration will leverage Kenox Pharmaceuticals’ extensive expertise in nasal and inhaled pharmaceutical development and manufacturing. The focus of this joint effort is to accelerate the preclinical development of novel therapies designed to enhance mucosal immunity in individuals with compromised immune systems.
The grant will advance Lactiga’s platform sIgA technology while expanding Kenox’s capabilities in inhaled and intranasal biologic delivery systems.
“We are thrilled to partner with Lactiga and contribute to the development of these potentially life-changing therapies,” said Sitaram Velaga, President and CEO. “This collaboration, combined with the prestigious NIH grant, underscores the immense potential of this innovative approach to address the unmet needs of immunodeficient patients.”
“Immunologists have long sought a nasal sIgA spray to reduce recurrent respiratory infections, especially in compromised individuals a major unmet medical need costing the healthcare system billions of dollars. Through our partnership with Kenox, we are making a first-in-class intranasal sIgA therapy a reality,” said Rikin Mehta, CEO & Cofounder of Lactiga.
